Bio-Techne Declares $0.08 Quarterly Dividend
The payout is conditional on the pending Merck KGaA transaction not closing by November 13, 2026.
Updated on Nov. 4, 2026 in Corporate Finance
Bio-Techne Corporation's Board of Directors declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable November 23, 2026, to shareholders of record at the close of business on November 13, 2026.
Why it matters
The payment depends on whether the company's pending transaction with Merck KGaA, Darmstadt, Germany closes on or before the record date. For Minnesota shareholders and the company's Minneapolis-based operations, the outcome of that deal will determine whether the dividend is paid as scheduled.
The declaration sets a $0.08 per-share quarterly payout, with payment tied to the pending Merck KGaA transaction rather than to company performance alone. Whether the dividend is ultimately paid depends on a transaction timeline that the company has not resolved in the announcement.
The players
Bio-Techne Corporation
A global life sciences company that provides tools and bioactive reagents to researchers and clinical laboratories, reporting over $1.2 billion in fiscal 2026 net sales.
Merck KGaA, Darmstadt, Germany
A German multinational science and technology company whose pending transaction with Bio-Techne determines whether the quarterly dividend will be paid.
The details
The Board declared the dividend for the quarter ended September 30, 2026, with payment set for November 23, 2026. Payment is conditional: if the transaction with Merck KGaA, Darmstadt, Germany closes on or before November 13, 2026, the dividend will not be paid. Bio-Techne is a global life sciences company that provides tools and bioactive reagents.
Timeline
September 30, 2026: Quarter end for which the dividend is declared.
November 13, 2026: Dividend record date and transaction closing deadline.
November 23, 2026: Scheduled dividend payment date.
Market Dynamics
The conditional structure of this quarterly payout ties a routine capital return to an outstanding acquisition timeline, a pattern that makes the dividend's status depend on deal-closing rather than only on earnings. Future payouts will be considered by the Board on a quarterly basis as applicable.
Shareholders of record on November 13, 2026 will receive $0.08 per share on November 23, 2026 only if the Merck KGaA transaction does not close on or before that record date. Investors holding Bio-Techne shares should track the transaction's closing status before that date to know whether the payout will be made.
The takeaway
The dividend's payment rests on a single condition, the timing of the Merck KGaA transaction, so shareholders should watch the deal's closing date ahead of the November 13, 2026 record date.
What happens next
The dividend payment on November 23, 2026 depends on whether the Merck KGaA transaction closes by the November 13, 2026 record date.
Further reading
For related coverage, explore Corporate Finance news across Minnesota.
Source note: This article includes information reported by Globe Gazette.
